1. Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study
- Author
-
Zhe-Yu Hu, Yu Tang, Liping Liu, Ning Xie, Can Tian, Binliang Liu, Lixin Zou, Wei Zhou, Yikai Wang, Xuefeng Xia, and Quchang Ouyang
- Subjects
Late-line therapy ,Druggable circulating tumor DNA alterations ,Genetic alterations of functional pathways ,Progression-free survival (PFS) ,Disease control rate (DCR) ,Medicine (General) ,R5-920 - Abstract
Summary: Background: After multiple lines of therapies, no guideline or consensus is currently available for the treatment of patients with metastatic breast cancer. This study aims to evaluate the efficacy of a novel re-subtyping and treatment strategy based on ctDNA alterations. Methods: This observational, multicentre study recruited 223 patients with metastatic breast cancer intending to receive late-line therapy from Dec 1, 2016, to June 31, 2019. This study took place in Hunan Cancer Hospital, the Forth Hospital of Changsha and Zhuzhou Central Hospital in China. ctDNA alterations were assessed by next-generation sequencing (NGS). Patients with druggable ctDNA alterations were treated with corresponding targeted drugs which are clinically available. Other patients received physician-chosen treatment. This study was registered with ClinicalTrials.gov, NCT05079074. Findings: The progression-free survival (hazard ratio: 0.45, 95% Confidence Interval (CI): 0.33-0.62, P
- Published
- 2022
- Full Text
- View/download PDF